Mankind Pharma inches up on inking pact with AstraZeneca Pharma India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Mankind Pharma is currently trading at Rs. 2165.60, up by 3.30 points or 0.15% from its previous closing of Rs. 2162.30 on the BSE.
The scrip opened at Rs. 2156.80 and has touched a high and low of Rs. 2195.95 and Rs. 2154.60 respectively. So far 1732 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 2297.00 on 08-Feb-2024 and a 52 week low of Rs. 1240.75 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 2200.25 and Rs. 2121.40 respectively. The current market cap of the company is Rs. 86619.24 crore.
The promoters holding in the company stood at 76.51%, while Institutions and Non-Institutions held 16.53% and 6.97% respectively.
Mankind Pharma has entered into an agreement with AstraZeneca Pharma India for exclusive distribution of AstraZeneca’s budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license.
With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
